Tatiana Prowell: Liquid biopsy – Is there benefit? We don’t know

Tatiana Prowell shared on X: .

“Liquid biopsy has not been shown to improve outcome in early breast cancer. I have seen many for 2nd opinions with EBC and tumor markers and/or ctDNA sent by their doctors.

There is harm in the form of (currently non-actionable) worry. Is there benefit? We don’t know.”

Source: Tatiana Prowell/X

Tatiana Prowell is an Associate Professor of Oncology in the Division of Women’s Malignancies at the Johns Hopkins Kimmel Comprehensive Cancer Center and Breast Cancer Scientific Liaison to the U.S. Food and Drug Administration.

She was the principal architect of FDA’s policy on accelerated approval using pathological complete response as a novel regulatory endpoint in the neoadjuvant high-risk breast cancer setting, and a member of the Biden Cancer Moonshot Blue Ribbon Panel Cancer Immunology Working Group.

A frequent public speaker, she is a three-time recipient of FDA’s Excellence in Communication Award. She is a past Giants of Cancer Care Award finalist, the recipient of the 2019 John and Samuel Bard Medal in Science or Medicine, and the recipient of a 2020 Webby Special Achievement Award for her effective use of social media during the pandemic.